US Oncology Research, The US Oncology Network and McKesson Specialty Health
Affiliated Investigators Participate in 90 Studies Featured at ASCO 2013

Studies have a wide-range of focus including trials with novel chemotherapy regimens, radiation therapy, vaccine therapy, trials with small molecules targeting sub-sets of cancer, and novel combinations of therapies

The Woodlands, Texas (May 28, 2013) — More than 85 leading investigators affiliated with US Oncology Research, The US Oncology Network and McKesson Specialty Health participated in 90 studies that will be presented, displayed or published at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO) held May 31-June 4 at McCormick Place in Chicago. Of those studies, 11 will be presented as oral presentations, three as educational/special sessions and 45 as poster presentations.

Daniel Von Hoff, M.D., F.A.C.P., chief scientific officer for US Oncology Research and physician in chief and director of translational research at the Translational Genomics Research Institute (TGen), is presenting a study titled, “Results of a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA19-9 correlates.” During the oral presentation, Dr. Von Hoff will detail the results of the study and explain why the outcomes could have a significant impact on how patients with pancreatic cancer are treated.

“Studies such as this one allow us to make significant strides in our fight against advanced pancreatic cancer, a disease that is very difficult to treat because early detection is so difficult,” said Dr. Von Hoff. “More than 850 patients with metastatic pancreatic cancer treated at over 150 community and academic centers participated in this important trial (based on solid basic science), which is a new standard in the treatment of patients with pancreatic cancer and could become a backbone for new regimens.”

Dr. Von Hoff was also involved in a study titled, “Integrating molecular profiling into cancer treatment decision making: Experience with over 35,000 cases,” as another oral presentation at the ASCO annual meeting. This trial is evidence of the growing shift in clinical cancer research, where more investigators are focusing on biomarkers and molecular diagnostics to better understand the biology of a patient’s tumor. The study also provides important leads for clinical trials with both established and investigational new agents.

“Our affiliated investigators were involved in 90 studies featured at ASCO this year, and many of those studies involve a biomarker or targeted molecule,” said Lisa Holland, vice president of US Oncology Research, which is supported by McKesson Specialty Health. “We are honored to participate in designing and conducting clinical trials that focus on the science, looking for the most effective opportunities that will benefit a patient’s care. For example, we had the opportunity to lead enrollment in the U.S. for several studies with novel combination therapies as well as studies that have been practice-changing for patients affected by cancer. Due to the size and connectivity of our network, we are fortunate to be able to identify patients for the smaller, targeted trials, as well as continue to accrue on larger trials across the network. We are committed to supporting our affiliated investigators with clinical trial opportunities for patients and are very proud of their strong presence at this year’s ASCO meeting.”

A part of McKesson Specialty Health, US Oncology Research enables community-based oncologists, many of whom are affiliated with The US Oncology Network, to participate in clinical research studies. US Oncology Research has a long history of bringing innovative and successful

Names in bold are affiliated with US Oncology Research, The US Oncology Network or McKesson Specialty Health
agents to market. To date, the physicians affiliated with US Oncology Research have played a role in the development of 46 FDA-approved cancer fighting therapies.

**ASCO presentations that affiliated investigators are part of:**

**Editor Note:** Please contact Claire Crye (281) 863-6783 / (281) 825-9927 or via email at Claire.Crye@mckesson.com to set up an interview with any investigator in bold.

**Oral Presentations:**

1. **Saturday, June 1, 1:30pm - 1:45pm, E354a**
   Tolerability and activity of combinations of the PI3Kδ inhibitor idelalisib (GS-1101) with rituximab and/or bendamustine in patients with previously treated, indolent non-Hodgkin lymphoma (iNHL): Updated results from a phase I study

2. **Saturday, June 1, 1:30pm-1:45pm, E354a**
   Preliminary results of PI3Kδ inhibitor idelalisib (GS-1101) treatment in combination with everolimus, bortezomib, or bendamustine/rituximab in patients with previously treated mantle cell lymphoma (MCL)

3. **Saturday, June 1, 3:45pm - 4:00pm, S406**
   OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIIB/C and IV melanoma

4. **Sunday, June 2, 8:15am-8:30am, E354b**
   Integrating molecular profiling into cancer treatment decision making: Experience with over 35,000 cases
   Zoran Gatalica, Sherri Millis, Sting Chen, Gargi Dan Basu, Wenhsiang Wen, Les Paul, Ryan P. Bender, **Daniel D. Von Hoff**

5. **Sunday, June 2, 9:15am - 9:30am, N Hall B1**
   Phase III, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and vinorelbine in trastuzumab-resistant, advanced breast cancer (BOLERO-3)
   Ruth O'Regan, Mustafa Ozguroglu, Fabrice Andre, Masakazu Toi, Guy Heinrich Maria Jerusalem, Sharon Wilks, Claudine Isaacs, Binghe Xu, Norikazu Masuda, Francis P. Arena, Denise Aysel Yardley, Yoon Sim Yap, Pabak Mukhopadhyay, Shyanne Douma, Mona El-Hashimi, Tanya Taran, Tarek Sahmoud, David Edward Lebwohl, Luca Gianni

6. **Monday, June 3, 11:15am-11:30am, E Hall D1**
   Results of a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA19-9 correlates
7. Monday, June 3, 4:00pm - 4:15pm, E Hall D2
Randomized, open-label, phase III study of pemetrexed plus carboplatin (PemC) followed by maintenance pemetrexed versus paclitaxel/carboplatin/bevacizumab (PCB) followed by maintenance bevacizumab in patients with advanced nonsquamous (NS) non-small cell lung cancer (NSCLC)

8. Mon, June 3, 4:15pm - 4:30pm, E Hall D2
A phase III study of pemetrexed (Pem) plus carboplatin (Cb) plus bevacizumab (Bev) followed by maintenance pem plus bev versus paclitaxel (Pac) plus cb plus bev followed by maintenance bev in stage IIIb or IV nonsquamous non-small cell lung cancer (NS-NSCLC): Overall and age group results
Mark A. Socinski, Jyoti D. Patel, Edward B. Garon, Ramaswamy Govindan, Craig H. Reynolds, David R. Spigel, Mark R. Olsen, Jingyi Liu, Susan C. Guba, Philip Bonomi

9. Monday, June 3, 5:30pm - 5:45pm, E Hall D2
Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
David R. Spigel, Scott N. Gettinger, Leora Horn, Roy S. Herbst, Leena Gandhi, Michael S. Gordon, Cristina Cruz, Paul Conkling, Philippe Alexandre Cassier, Scott J. Antonia, Howard A. Burris, Gregg Daniel Fine, Ahmad Mokatrin, Marcin Kowanetz, Xiaodong Shen, Daniel S. Chen, Jean-Charles Soria

10. Tuesday, June 4, 9:45am - 10:00am, E Hall D1
Charles Andrew Butts, Mark A. Socinski, Paul Mitchell, Nick Thatcher, Libor Havel, Maciej Jerzy Krzakowski, Sergiusz Nawrocki, Tudor-Eliade Ciuleanu, Lionel Bosquée, Jose Manuel Trigo Perez, Alexander I. Spira, Lise Tremblay, Jan Nyman, Rodryg Ramlau, Christoph Helwig, Martin H. Falk, Frances A. Shepherd

11. Tuesday, June 4, 10:15am - 10:30am, E Hall D1
A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy with or without cetuximab for stage III non-small cell lung cancer: Results on radiation dose in RTOG 0617

Educational and Special Sessions:

1. Friday, May 31, 3:45 pm – 6:00 pm
Career Choices: Options in Academia, Practice, Industry, and Government
Dr. Fadi Braiteh

Names in bold are affiliated with US Oncology Research, The US Oncology Network or McKesson Specialty Health
2. Saturday, June 1, 4:45 pm – 6:00 pm
Is Age Just a Number? Adjuvant Therapy Decision Making for Older and/or Frail Patients with Cancer
Dr. Cynthia Osborne

3. Monday, June 3, 1:15 pm – 2:30 pm
Women in Oncology: Challenges and Keys to Success
Dr. Debra Patt

Poster Presentations:

1. Saturday, June 1, 1:15pm - 5:00pm, S Hall A2
Erubulin mesylate (Erib) plus capecitabine (X) for adjuvant treatment in post-menopausal estrogen receptor–positive (ER+) early-stage breast cancer: Phase II, multicenter, single-arm study
John W. Smith, Jessica Rege, Hina Maniar, James Song, David Cox, Joyce O'Shaughnessy

2. Saturday, June 1, 1:15pm - 5:00pm, S Hall A2
ER as a predictor of early breast cancer (EBC) outcomes in patients

3. Saturday, June 1, 1:15pm - 5:00pm, S Hall A2
Identification of the activated form of the progesterone receptor (PR) in breast cancer (BC)
Jacques Bosq, Jean-Michel Caillaud, Carol A. Lange, Suzanne A. W. Fuqua, Joyce O'Shaughnessy, Erard M. Gilles, Alexander A. Zukiwski, Jacques Bonneterre

4. Saturday, June 1, 1:15pm - 5:00pm, S Hall A2
Independent characterization by duel staining of progesterone receptor (PR) and estrogen receptor (ER) in breast cancer (BC)
Alexander A. Zukiwski, Jean-Michel Caillaud, Jacques Bosq, Suzanne A. W. Fuqua, Carol A. Lange, Joyce O'Shaughnessy, Erard M. Gilles, Jacques Bonneterre

5. Saturday, June 1, 1:15pm - 5:00pm, S Hall A2
Etirinotecan pegol (EP) target-specific pharmacodynamic (PD) biomarkers measured in circulating tumor cells (CTCs) from patients in the phase III BEACON study in patients with metastatic breast cancer (mBC)
Ute Hoch, Dennis G. Fry, Yen Lin Chia, Katie Caygill, Alison L. Hannah, Edith A. Perez, Javier Cortez, Ahmad Awada, Joyce O'Shaughnessy, Christopher Twelves, Hope S. Rugo, Seock-Ah Im, Binghe Xu, Kenna Lynn Anderes, Darren W. Davis

6. Saturday, June 1, 3:00pm - 6:00pm, E253
Neurocognitive function (NCF) outcomes in patients with glioblastoma (GBM) enrolled in RTOG 0825
Jeffrey Scott Wefel, Stephanie L. Pugh, Terri S. Armstrong, Mark R. Gilbert, Minhee Won, Merideth M. Wendland, David Brachman, Ritsuko Komaki, Ian R. Crocker, H. Ian Robins, R. Jeffrey Lee, Minesh P. Mehta

7. Monday, June 3, 8:00am - 12:00pm, E450a
BTTC08-01: A phase II study of bevacizumab and erlotinib after radiation therapy and temozolomide in patients with newly diagnosed glioblastoma (GBM) without MGMT promoter methylation

8. Saturday, June 1, 8:00am - 11:45am, S Hall A2
RTOG 0913: A phase I study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma
Praaksh Chinnaiyan, Minhee Wen, Patrick Y. Wen, Amyn Rojiani, Merideth M. Wendland, Thomas A. DiPetrillo, Benjamin W. Corn, Minesh P. Mehta

9. Monday, June 3, 8:00am - 11:45am, S Hall A2
Phase Ib safety trial of CVX-060, an intravenous humanized monoclonal CovX body inhibiting angiopoietin 2 (Ang-2), with axitinib in patients with previously treated metastatic renal cell cancer (RCC)
Ashwin Gollerkeri, Michael S. Gordon, John M. Burke, Ralph Hauke, Jiri Tomasek, Donald A. Richards, Christopher DiSimone, Scott S. Tykodi, Amit R. Mehta, Charles Chen, Rachelle Perea, Nicholas J. Vogelzang

10. Sunday, June 2, 8:00am - 11:45am, S Hall A2
SPIRITT (study 20060141): A randomized phase II study of FOLFIRI with either panitumumab (pmab) or bevacizumab (bev) as second-line treatment (tx) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC)
Allen Lee Cohn, J. Randolph Hecht, Shaker Dakhil, Mansoor N. Saleh, Bilal Piperdi, Vivian Jean M. Cline-Burkhartd, Ying Tian, William Y. Go

11. Sunday, June 2, 8:00am - 11:45am, S Hall A2
Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic CRC, gastric cancer (GC), SCCHN, or other tumors

12. Sunday, June 2, 8:00am - 11:45am, S Hall A2
A pilot phase II multicenter study of nab-paclitaxel (Nab-P) and gemcitabine (G) as preoperative therapy for potentially resectable pancreatic cancer (PC)

13. Sun, June 2, 8:00am - 11:45am, S Hall A2
CA19-9 decrease at 8 weeks as a predictor of overall survival (OS) in a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients with metastatic pancreatic cancer (MPC)

14. Sunday, June 2, 8:00am - 11:45am, S Hall A2
Prognostic factors (PFs) of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients (pts) with metastatic pancreatic cancer (MPC)

Names in bold are affiliated with US Oncology Research, The US Oncology Network or McKesson Specialty Health
15. Sunday, June 2, 8:00am - 11:45am, S Hall A2
   **A phase II clinical trial of ganetespib (STA-9090) in previously treated patients with advanced esophagogastric cancers**
   Eunice Lee Kwak, Lipika Goyal, Thomas Adam Abrams, Amanda Carpenter, Brian M. Wolpin, **Raymond Couric Wadlow**, Jill N. Allen, Rebecca Suk Heist, Nadine Jackson Mc Cleary, Jennifer A. Chan, Wolfram Goessling, Deborah Schrag, Colleen Evans, Kimmie Ng, Peter C. Enzinger, David P. Ryan

16. Sunday, June 2, 8:00am - 11:45am, S Hall A2
   **Results of a phase I/II study (NCT01365559) of carfilzomib (CFZ) replacing bortezomib (BTZ) in BTZ-containing regimens for BTZ-treated patients (pts) with relapsed and refractory multiple myeloma (MM)**
   James R. Berenson, James D. Hilger, Robert Dichmann, **Dipti Patel-Donnelly**, Ralph V. Boccia, Alberto Bessudo, Laura Stampleman, Donald Gravenor, Shahrooz Eshaghian, Hilda Chamras, Youram Nassir, Regina A. Swift, Robert A. Vescio

17. Monday, June 3, 8:00am - 11:45am, S Hall A2
   **A phase I/II trial of BNC105P with everolimus in metastatic renal cell carcinoma (mRCC) patients: Updated phase I results of the Disruptor-1 trial**
   John Sarantopoulos, Long H. Dang, Richard C. Lauer, Alexander Starodub, Ralph J. Hauke, Matt D. Galsky, Kathryn A. Bylow, **Charles Lance Cowey**, David C. Bibby, Gabriel Kremmidiotis, Elizabeth E. Doolin, Tina C. Lavranos, Jose Luis Iglesias, Guru Sonpavde, Theodore Logan, Noah M. Hahn, Christopher Sweeney, **Thomas E. Hutson**

18. Mon, June 3, 8:00am - 11:45am, S Hall A2
   **Rates of dose adjustment in patients treated with tivozanib versus sorafenib in the phase III TIVO-1 study**
   **Thomas E. Hutson**, Dmitry Nosov, Mihai Harza, Brooke Esteves, Andrew Louis Strahs, Anna Berkenblit, Robert John Motzer

19. Monday, June 3, 8:00am - 11:45am, S Hall A2
   **Impact of cytoreductive nephrectomy on disease-specific survival (DSS) in the cytokine and targeted therapy eras: Age- and TNM-stage matched analysis of SEER data**
   Rebecca A. Nelson, Nicholas J. Vogelzang, Sumanta Kumar Pal

20. Saturday, June 1, 8:00am - 12:00pm, E450a
    **A prognostic model for predicting overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) after docetaxel**
    Kim N. Chi, Thian San Kheoh, Charles J. Ryan, Arturo Molina, Joaquim Bellmunt, Nicholas J. Vogelzang, Dana E. Rathkopf, Karim Fizazi, Philip W. Kantoff, Jinhui Li, Johann Sebastian De Bono, Howard I. Scher

21. Saturday, June 1, 8:00am - 12:00pm, E450a
    **A randomized phase II study evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy (ADT) in biochemically recurrent prostate cancer (BRPC): Immune results**
    Emmanuel S. Antonarakis, Adam S Kibel, George Adams, Lawrence Ivan Karsh, Aymen Elfiky, Neal D. Shore, Nicholas J. Vogelzang, John M. Corman, Robert Claude Tyler, Candice McCoy, Yang Wang, Nadeem A. Sheikh, Charles G. Drake

22. Saturday, June 1, 8:00am - 12:00pm, E450a
    **Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in metastatic castration-resistant prostate cancer (mCRPC) previously treated with a taxane**

---

Names in bold are affiliated with US Oncology Research, The US Oncology Network or McKesson Specialty Health
An exploratory analysis of bone scan lesion area (BSLA), circulating tumor cell (CTC) change, pain reduction, and overall survival (OS) in patients (pts) with castration-resistant prostate cancer (CRPC) treated with cabozantinib (cab) Updated results of a phase II nonrandomized expansion (NRE) cohort
Howard I. Scher, Matthew R. Smith, Christopher Sweeney, Paul Gettys Corn, Christopher Logothetis, Nicholas J. Vogelzang, David C. Smith, Maha Hussain, Daniel J. George, Johann Sebastian De Bono, Celestia S. Higano, Eric Jay Small, Jonathan Goldin, Matthew S. Brown, Dana T. Aftab, Mojtaba Noursalehi, Aaron Weitzman, Ethan M. Basch

Impact of prior docetaxel (D) on sipuleucel-T (sip-T) product parameters in PROCEED patients (pts)
Celestia S. Higano, Andrew J. Armstrong, Matthew R. Cooperberg, Philip W. Kantoff, James Bailen, Raoul S. Concepcion, Vahan Kassabian, Shaker R. Dakhil, Steven E. Finkielstein, Jeffrey L. Vacirca, Robert M. Rifkin, Andrew Sandler, Candice McCoy, James Boyd Whitmore, Robert Claude Tyler, A. Oliver Sartor

Hematologic safety of Ra-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases from the phase III ALSYMPA trial
Chris Parker, Jose E. Garcia-Vargas, C. Gillies O'Bryan-Tear, Fang Fang, Nicholas J. Vogelzang

Results from a phase I study of enzalutamide in combination with docetaxel in men with prostate cancer
Mark T. Fleming, Dana E. Rathkopf, Jackie Gibbons, Amy C. Peterson, Alison Hannah, David Forer, Howard I. Scher, Michael J. Morris

Efficacy and safety of radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases who did or did not receive prior docetaxel (D) in the phase III ALSYMPA trial
Nicholas J. Vogelzang, Svein Inge Helle, Dag Clement Johannessen, Joe M. O'Sullivan, Jose E. Garcia-Vargas, C. Gillies O'Bryan-Tear, Minghua Shan, Chris Parker

Impact of pathways on chemotherapy administration before death
Marcus A. Neubauer, Jody S. Garey, Brian Turnwald, Robyn K. Harrell, Josh Howell, Jad Hayes, Debajyoti Bhowmik, J. Russell Hoverman, Barry Don Brooks, Roy Beveridge

Updated use of first-line chemotherapy for advanced pancreatic cancer: FOLFIRINOX versus gemcitabine
Treatment response monitoring in chronic phase CML (CP-CML) patients receiving tyrosine kinase inhibitor (TKI) therapy in The US Oncology Network
Kathryn S. Kolibaba, Hsingwen Chung, Rahul Dhanda, Debra Rembert, Stephanie Lustgarten, Jing L. Marantz, Hui Huang

31. Sunday, June 2, 8:00am - 11:45am, S Hall A2
Variation in health-related quality of life (HRQOL) by line of therapy, age, and gender among patients with chronic lymphocytic leukemia
Christopher Flowers, Charles Michael Farber, Ian Flinn, David L. Grinblatt, Neil E. Kay, Thomas J. Kipps, Mark Kozloff, Nicole Lamanna, Susan Lerner, Jeff Porter Sharman, Mark Adam Weiss, Arlene S. Swern, Zeba M. Khan, Thomas K. Street, Kristen A. Sullivan, Ren Yu, Chris L. Pashos

32. Sunday, June 2, 8:00am - 11:45am, S Hall A2
Types, frequency, and adherence of molecular tests in chronic myelogenous leukemia at chronic phase (CML-CP) in the U.S. community setting
Clara Chen, Lei Chen, Rahul Dhanda, Hsingwen Chung, Debajyoti Bhowmik, Solveig Ericson, Nicholas DiBella

33. Sunday, June 2, 8:00am - 11:45am, S Hall A2
A 36-month analysis of treatment patterns and outcomes in patients with lower-risk myelodysplastic syndromes from a prospective observational study
Roger M. Lyons, Billie J. Marek, Carole S. Paley, Jason Esposito, Lawrence E. Garbo, Nicholas J. DiBella, Guillermo Garcia-Manero

34. Saturday, June 1, 8:00am - 11:45am, S Hall A2
Molecular marker assessments for epidermal growth factor receptor (EGFR) expression by immunohistochemistry (IHC) and histoscore (H-score) in the phase III SELECT trial
Edward S. Kim, Sreenivas Chittoor, Craig H. Reynolds, Lorinda Simms, Scott Saxma

35. Saturday, June 1, 8:00am - 11:45am, S Hall A2
Translational research (TR) results from pointbreak: A randomized, open-label, phase III study of pemetrexed (Pem)+carboplatin (Cb)+bevacizumab (Bev) followed by maintenance pem+bev (Pem Arm) versus paclitaxel (Pac)+cb+bev followed by maintenance bev (Pac Arm) in patients (pts) with stage IIIB or IV nonsquamous non-small cell lung cancer (ns-NSCLC)
Edward B. Garon, Jyoti D. Patel, Scott Myrand, Tuan Nguyen, Craig H. Reynolds, David R. Spigel, Robert C. Hermann, Jingyi Liu, Susan C. Guba, Ramaswamy Govindan, Mark A. Socinski, Philip Bonomi

36. Sunday, June 2, 8:00am - 11:45am, S Hall A2
Certification and role of local pathologists for diffuse large B-cell lymphoma (DLBCL) subtyping and eligibility determination in the phase II PYRAMID study

37. Sunday, June 2, 8:00am - 11:45am, S Hall A2
Different safety profiles of first-line bendamustine-rituximab (BR), R-CHOP, and R-CVP in an open-label, randomized study of indolent non-Hodgkin lymphoma (NHL) and mantle cell lymphoma (MCL): The BRIGHT study
David MacDonald, Richard van der Jagt, John M. Burke, Brad S. Kahl, Peter Wood, Tim E. Hawkins, Mark Hertzberg, Yiu-Lam Kwan, David Simpson, Michael Craig, Kathryn S.
Kolibaba, Samar Issa, Regina Clementi, Doreen M. Hallman, Mihaela C. Munteanu, Ling Chen, Ian Flinn

38. Sun, June 2, 8:00am - 11:45am, S Hall A2
Changes in patient-reported outcomes in patients diagnosed with and treated for multiple myeloma in the Connect MM registry

39. Sunday, June 2, 8:00am - 11:45am, S Hall A2
Early mortality (EM) for newly diagnosed multiple myeloma (NDMM) in the Connect MM U.S. registry

40. Monday, June 3, 8:00am - 12:00pm, S405
A phase II study of the multitargeted kinase inhibitor lenvatinib in patients with advanced BRAF wild-type melanoma
Steven O'Day, Rene Gonzalez, Kevin Kim, Bartosz Chmielowski, Richard Kefford, Georgina Long, Carmen Loqui, Charles Lance Cowey, Axel Hauschild, John D. Hainsworth, Peter Hersey, Frances Boyle, T. R. Jeffry Evans, Omid Hamid, Nicole Meneses, Corina Andresen, Min Ren, James P. O'Brien, Keith Flaherty

41. Monday, June 3, 1:15pm - 5:00pm, S Hall A2
Bridging to survivorship in breast cancer: Learning how treatment impacts mental health among early-stage breast cancer survivors
Debra A. Patt, Janet L. Espirito, Brian Turnwald, Robyn K. Harrell, Debajyoti Bhowmik, J. Russell Hoverman, Barry Don Brooks, Neelima Denduluri, Roy A. Beveridge

42. Monday, June 3, 1:15pm - 5:00pm, S Hall A2
Bridging to survivorship in breast cancer: How BMI weighs in
Janet L. Espirito, Brian Turnwald, Robyn K. Harrell, Debajyoti Bhowmik, Neelima Denduluri, Barry Don Brooks, J. Russell Hoverman, Roy A. Beveridge, Debra A. Patt

43. Saturday, June 1, 1:15pm - 5:00pm, S Hall A2
Identification of the activated form of the progesterone receptor (PR) in breast cancer (BC)
Jacques Bosq, Jean-Michel Caillaud, Carol A. Lange, Suzanne A. W. Fuqua, Joyce O'Shaughnessy, Erard M. Gilles, Alexander A. Zukiwski, Jacques Bonneterre

44. Saturday, June 1, 1:15pm - 5:00pm, S Hall A2
Independent characterization by duel staining of progesterone receptor (PR) and estrogen receptor (ER) in breast cancer (BC)
Alexander A. Zukiwski, Jean-Michel Caillaud, Jacques Bosq, Suzanne A. W. Fuqua, Carol A. Lange, Joyce O'Shaughnessy, Erard M. Gilles, Jacques Bonneterre

45. Saturday, June 1, 1:15pm - 5:00pm, S Hall A2
Initial results from the 21-gene breast cancer assay registry: A prospective observational study in patients (pts) with ER+, early-stage invasive breast cancer (EBC)
Trials in Progress Posters:

1. Saturday, June 1, 1:15pm - 5:00pm, S Hall A2
   Human epidermal growth factor receptor 2 (HER2) suppression with the addition of lapatinib to trastuzumab in HER2-positive metastatic breast cancer (HALT: LPT112515)

2. Saturday, June 1, 8:00am - 11:45am, S Hall A2
   Phase I lead-in to a 2x2x2 factorial trial of dose-dense temozolomide, memantine, mefloquine, and metformin as postradiation adjuvant therapy of glioblastoma (GBM)

3. Sat, June 1, 1:15pm - 5:00pm, S Hall A2
   A randomized, multicenter, double-blind phase III study of palbociclib (PD-0332991), an oral CDK 4/6 inhibitor, plus letrozole versus placebo plus letrozole for the treatment of postmenopausal women with ER(+) HER2(-) breast cancer who have not received any prior systemic anticancer treatment for advanced disease
   Richard S. Finn, Veronique Dieras, Karen A. Gelmon, Nadia Harbeck, Stephen E. Jones, Maria Koehler, Miguel Martin, Hope S. Rugo, Seock-Ah Im, Masakazu Toi, Eric Roland Gauthier, Xin Huang, Sophia Randolph, Dennis J. Slamon

4. Saturday, June 1, 1:15pm - 5:00pm, S Hall A2
   MERiDiAN: A phase III, randomized, double-blind study of the efficacy, safety, and associated biomarkers of bevacizumab plus paclitaxel compared with paclitaxel plus placebo, as first-line treatment of patients with HER2-negative metastatic breast cancer
   David Miles, Leonardo Faoro, Yan V. Wang, Joyce O'Shaughnessy

5. Sun, June 2, 8:00am - 11:45pm, S Hall A2
   A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated chronic lymphocytic leukemia (CLL)
   Herbert Aaron Eradat, Steven E. Coutre, Jacqueline Claudia Barrientos, Kanti Roop Rai, Charles Michael Farber, Peter Hillmen, Jeff Porter Sharman, Paolo Ghia, Bertrand Coiffier, Jan Andrzej Walewski, Zwi N. Berneman, Susan Mary O'Brien, Jennifer R. Brown, Sissy Peterman, Roger D. Dansey, Thomas Michael Jahn, Paula Cramer, Michael J. Hallek

6. Monday, June 3, 8:00am - 11:45am, S Hall A2
   A phase I dose-escalation study of TKM-080301, a RNAi therapeutic directed against polo-like kinase 1 (PLK1), in patients with advanced solid tumors: Expansion cohort evaluation of biopsy samples for evidence of pharmacodynamic effects of PLK1 inhibition

7. Monday, June 3, 1:15pm - 5:00pm, S Hall A2
**A pilot study utilizing molecular profiling to find potential targets and select individualized treatments for patients with metastatic breast cancer**

Gayle S. Jameson, Emanuel Petricoin, Jasgit C. Sachdev, Lance A. Liotta, David Loesch, Stephen Patrick Anthony, Manpreet Chadha, Mariaelena Pierobon, Alex Reeder, Monica Fulk, Linda Vocila, Nina Cantafio, Bryant Dunetz, Nicholas J. Robert

---

**Poster Discussions:**

1. **Tuesday, June 4, 8:00am - 12:00pm, E450b**

   *Nomogram to estimate the activity of second-line therapy for advanced urothelial carcinoma (UC)*

   Guru Sonpavde, Gregory Russell Pond, Neeraj Agarwal, Tony K. Choueiri, Angela Q. Qu, Ronan Fougeray, Yacine Salhi, David J. Vaughn, Nicholas David James, Guenter Niegisch, Peter Albers, Matt D. Galsky, Yu-Ning Wong, Walter Michael Stadler, Peter H. O'Donnell, Nicholas J. Vogelzang, Srikala S. Sridhar, Yoo-Joung Ko, Cora N. Sternberg, Joaquim Bellmunt

2. **Saturday, June 1, 8:00am - 12:00pm, S405**

   *Update on a phase I study of the selective PI3Kδ inhibitor idelalisib (GS-1101) in combination with rituximab and/or bendamustine in patients with relapsed or refractory CLL*


3. **Saturday, June 1, 1:15pm - 5:15pm, S450b**

   *A phase I study of cediranib (NSC #732208) in combination with cisplatin and pemetrexed in chemonaive patients with malignant pleural mesothelioma (SWOG S0905)*

   Anne S. Tsao, James Moon, Ignacio Ivan Wistuba, Nicholas J. Vogelzang, Gregory Peter Kalemkerian, Mary Weber Redman, David R. Gandara

4. **Sunday, June 2, 8:00am - 12:00pm, E450a**

   *A multicenter open-label phase II study of the efficacy and safety of ganitumab (AMG 479), a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R) as second-line therapy in patients with recurrent platinum-sensitive ovarian cancer*


5. **Sunday, June 2, 8:00am - 12:00pm, E450a**

   *A phase II trial of lenvatinib in patients with advanced or recurrent endometrial cancer: angiopoietin-2 as a predictive marker for clinical outcomes*

   Ignace Vergote, Michael Teneriello, Matthew A. Powell, David S. Miller, Agustin A. Garcia, Olga N. Mikheeva, Tamás Pinter, Mariusz Bidzinski, Cristina Ligia Cebotaru, Jean Fan, Min Ren, Nicole Meneses, Yasuhiro Funahashi, Tadashi Kadowaki, James P. O'Brien, Richard T. Penson

6. **Sunday, June 2, 8:00am - 12:00pm, S405**

   *Burnout and career satisfaction among U.S. oncologists: Results of the 2012 ASCO survey*

   Tait D. Shanafelt, William Gradishar, Michael P. Kosty, Daniel Satele, Helen K. Chew, Leora Horn, Quyen Chu, Jeff Sloan, William B. Clark, Amy E. Hanley, John E. Pippen, Marilyn J. Raymond

---

Names in bold are affiliated with US Oncology Research, The US Oncology Network or McKesson Specialty Health
7. Sunday, June 2, 8:00am - 12:00pm, E450b
Exploratory analyses of efficacy and safety of pemetrexed (Pem) plus bevacizumab (Bev) and bev alone as maintenance therapy (MT) in patients (Pts) with stage IIIb or IV non-squamous non-small cell lung cancer (NS-NSCLC)

8. Sunday, June 2, 8:00am - 12:00pm, E450b
Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with docetaxel in KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase II/IIb trial

9. Monday, June 3, 1:15pm - 5:15pm, E450b
Secondary efficacy subanalysis by histology from the phase III BRIGHT study: First-line bendamustine-rituximab (BR) compared with standard R-CHOP/R-CVP for patients with advanced indolent non-Hodgkin lymphoma (NHL) or mantle cell lymphoma (MCL)
Ian Flinn, Richard H. C. Van Der Jagt, Brad S. Kahl, Peter Wood, Tim E. Hawkins, David MacDonald, Mark Hertzberg, Yu-Lam Kwan, David Simpson, Michael Craig, Kathryn S. Kolibaba, Samar Issa, Regina Clementi, Doreen M. Hallman, Mihaela C. Munteanu, Ling Chen, John M. Burke

Publication Only:

1. Final results from a trial of a combination herbal supplement for biochemically recurrent prostate cancer
Tanya B Dorff, Denice D Tsao-Wei, Debra Hawes, Shigang Xiong, David I. Quinn, Mitchell E. Gross, Gary Lieskovsky, Nicholas J. Vogelzang, Susan G. Groshen, Jacek K. Pinski

2. Treatment patterns, biomarker testing, and outcomes in patients with nonsquamous non-small cell lung cancer (NSCLC) receiving second-line treatment in The US Oncology Network
IWen Pan, Rajiv Mallick, Rahul Dhanda, Eric S. Nadler

3. Randomized phase III trial of pemetrexed (Pem)+carboplatin (Cb)+bevacizumab (Bev) followed by maintenance Pem+Bev (Pem arm) versus paclitaxel (Pac)+Cb+Bev followed by maintenance Bev (Pac arm) in patients (pts) with stage IIIb/IV non-squamous non-small cell lung cancer (nsNSCLC) (POINTBREAK): African American (AA) subset

4. Bevacizumab (BEV) use in disseminated choroid plexus papilloma (DCCP)
Mark Daniel Anderson, Brett James Theeler, Morris D. Groves, Marta Penas-Prado, W. K. Alfred Yung

5. Leucovorin shortage: Impact on leucovorin/levoleucovorin usage and tx choices in colon cancer patients treated in the United States
Ann Katler, Zhaohui Wang, Kimberly A. Bergstrom

Names in bold are affiliated with US Oncology Research, The US Oncology Network or McKesson Specialty Health
6. **Survival following initiation of everolimus for second-line treatment of metastatic renal cell carcinoma: Prognostic factors in clinical practice and comparison to clinical trials**
   Michael K.K. Wong, Eric Jonasch, Sumanta Kumar Pal, James E. Signorovitch, Peggy L. Lin, Zhimei Liu, Xufang Wang, Kenneth W. Culver, Jeffrey A. Scott, Daniel J. George, **Nicholas J. Vogelzang**

7. **Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: Analysis of two practice-based chart reviews**
   James E. Signorovitch, **Nicholas J. Vogelzang**, Sumanta Kumar Pal, Peggy L. Lin, Daniel J. George, Michael K.K. Wong, Zhimei Liu, Xufang Wang, Kenneth W. Culver, Jeffrey A. Scott, Eric Jonasch

8. **Association between guideline-adherent imaging and overall survival following second-line targeted therapy for metastatic renal cell carcinoma**
   Peggy L. Lin, Sumanta Kumar Pal, Eric Jonasch, James E. Signorovitch, Zhimei Liu, Kenneth W. Culver, Jeffrey A. Scott, **Nicholas J. Vogelzang**

9. **Medical oncologists’ clinical experiences and comfort levels with 20 recently approved agents**

10. **Early use of home health care on health care utilization for patients with advanced lung cancer**
    **Steven Rousey**, Kiran Krishan Lassi, Jodi Wieczorek, James Essler, Marie Brown, Sylvia Haroldson, Sue Sheppard, Kari Olson, Michelle O'Brien, Yunfei Wang

11. **Lack of effect of bendamustine on Fridericia corrected QT interval (QTcF) in a phase III study of bendamustine-rituximab in advanced indolent non-Hodgkin’s lymphoma (NHL) or mantle cell lymphoma (MCL)**
    **John M. Burke**, Ian Flinn, Michael Craig, Richard H. C. Van Der Jagt, David MacDonald, Doreen M. Hallman, Mihaela C. Munteanu

12. **Survival effects of erythropoiesis-stimulating agents (ESAs) in patients with breast cancer: A meta-analysis**
    Brian Leyland-Jones, Matti S. Aapro, Volker Moebus, Ulrike Nitz, Joyce O'Shaughnessy, Paolo Pronzato, Michael Untch, Dianne Tomita, Gerry C. Bohac

13. **A phase II pilot study of fosaprepitant (F) for the rescue of acute nausea and vomiting with moderately (MEC) or highly emetogenic chemotherapy (HEO) in adults**

14. **Treatment pattern trends of erythropoiesis-stimulating agents used for chemotherapy-induced anemia by U.S. community oncologists from 2008 to 2011**
    Zhaohui Wang, Ann Katler, Karen Todoroff, Kimberly A. Bergstrom

15. **Capturing and molecular analysis of tumor cells isolated from ascites fluid to predict response to treatment**
    Thomas Krahn, Michael Jeffers, **Daniel D. Von Hoff**, Mahesh Seetharam, Xinjun Liu, Phillip Sangwook Kim, Sharat Singh

---

**About US Oncology Research**
Supported by McKesson Specialty Health and The US Oncology Network, US Oncology Research draws from a network of experienced investigators and dedicated clinical staff who

Names in bold are affiliated with US Oncology Research, The US Oncology Network or McKesson Specialty Health
specialize in Phase I through Phase IV oncology clinical trials. US Oncology Research serves approximately 80 research sites and nearly 225 locations managing about 225 active trials at any given time. Physicians in the research network have enrolled more than 55,000 patients in over 1,200 trials since inception in 1992 and have contributed to the development of 46 cancer therapies approved by the FDA. For more information call (800) 482-6700, option 4 or visit www.usoncology.com/oncologists.

About The US Oncology Network
The US Oncology Network is one of the nation’s largest networks of integrated community-based oncology practices dedicated to advancing high-quality, evidence-based cancer care. A physician-led organization, The US Oncology Network unites like-minded physicians and clinicians around a common vision of improving patient outcomes and quality of life. Leveraging healthcare information technology, shared best practices, precise evidence-based guidelines and quality measurements, physicians within The US Oncology Network are pioneering new ways to achieve this vision. The US Oncology Network is committed to strengthening patient access to integrated care in local communities across the nation, including collaboration with a variety of regional payers, hospitals and academic institutions. The US Oncology Network is supported by McKesson Specialty Health, a division of McKesson Corporation focused on empowering a vibrant and sustainable community patient care delivery system. For more information, visit www.usoncology.com.

About McKesson Specialty Health
McKesson Specialty Health, a division of McKesson Corporation, empowers the community patient care delivery system by helping community practices advance the science, technology and quality of care. Through innovative clinical, research, business and operational solutions, facilitated by integrated technology systems, we focus on improving the financial health of our customers so they may provide the best care to their patients. For more information, visit www.mckessonspecialtyhealth.com.

Media Contact:
Claire Crye
(281) 863-6783 / (281) 825-9927
Claire.Crye@mckesson.com

###